Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ITI-1001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Immunomic Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : ITI will leverage Ichor’s TriGrid® Electroporation technology to increase cellular uptake of ITI-1001 when administered to patients with newly diagnosed Glioblastoma, or GBM.
Brand Name : ITI-1001
Molecule Type : Vaccine
Upfront Cash : Undisclosed
June 16, 2020
Lead Product(s) : ITI-1001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Immunomic Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?